Views:0 Author:Site Editor Publish Time: 2019-11-12 Origin:Site
Recently, many pharmaceutical listed companies have successively released information on the mid-year report. The mid-year report is a financial achievement of a company in the first half of the year. It not only reflects the value of the company in the market, but also helps investors predict the full-year performance and make a more comprehensive and in-depth assessment of the future development of the entire industry.
As an important part of the pharmaceutical industry, the pharmaceutical industry is experiencing the expansion of market demand, the favorable medical policy, and the changes in the competitive structure of the industry, and will soon enter a new development cycle, and pharmaceutical companies will also face opportunities and challenges. However, before thinking about how to grasp market opportunities and respond to future challenges, pharmaceutical companies must first make a summary from the results of the interim report.
The author understands that at present, Dongfulong Technology Co., Ltd. (hereinafter referred to as "Dongfulong"), Chutian Technology Co., Ltd. (hereinafter referred to as "Chutian Technology"), Canaan Technology Group Co., Ltd. (hereinafter referred to as "Canada" South Technology"), Hunan Qianshan Pharmaceutical Machinery Co., Ltd. (hereinafter referred to as "Qianshan Pharmaceutical Machinery"), Xinhua Medical Devices Co., Ltd. (hereinafter referred to as "Xinhua Medical") have issued interim reports. Judging from the performances released by these pharmaceutical companies, there are several happy ones.
For the above five pharmaceutical companies alone, only the net profit of Chutian Technology and Qianshan Pharmaceuticals showed an increase of 24.39% and 131.33% respectively. East Fulong, Canaan Technology, and Xinhua Medical were down 42.51%, 9.40%, and 10.82%, respectively. For such a situation, the industry will inevitably be curious about the factors of performance growth, and will also analyze the reasons for the decline in performance.